Twenty-four patients treated between January 2017 and December 2019 were selected from our institution’s clinical database for this retrospective study. According to FIGO stage classification [26], the local tumor stage of the patients was as follows: IB2 = 2, IIB = 6, IIIB = 3, IIIC1r = 8, IIIC2r = 5. All the patients underwent 45 to 50 Gy whole pelvic EBRT followed by 5 fractions of intracavitary/interstitial brachytherapy (IC/ISBT) with prescribed dose (PD) of 6 Gy. Nucletron standard tandem/ovoid (T/O) applicators and interstitial needles were used to deliver the IC/ISBT treatment. According to the different tumor shapes, the patients were treated with different combinations of applicators and needles as follows: 7 patients with 1 tandem 2 ovoids, 7 with 1 tandem 3 needles, 7 with 1 tandem 2 ovoids 2 needles, 2 with 1 tandem 2 ovoids 3 needles, 1 with 1 tandem 2 ovoids 4 needles. After the insertion of applications, all patients underwent CT scans using the Brilliance CT Big Bore (Philips, Amsterdam, Netherlands) with 3-mm slice thickness. These scans were transferred to the Oncentra Brachy v4.6 (Elekta Brachytherapy, Veneedal, The Netherlands), where high-risk clinical target volume (HR CTV), intermediate-risk clinical target volume (IR CTV), bladder, rectum, sigmoid and bowel were contoured in accordance with GEC ESTRO recommendation [27, 28]. The HR CTVs covered a wide range, between 22.6 and 140.8 cc (mean 68.0 cc). IR CTV was a 3-mm volumetric expansion of HR CTV while subtracting all OARs. We treated it as a target but also as a help structure to control high dose regions outside HR CTV during dose optimization. The dose volume constraints in this study followed NCCN clinical practice guidelines v. 3.2019 (see Table 1) [29]. The median of the constraint ranges and the EBRT dose of 45 Gy/25f were adopted for determining the dose volume constraints per one fraction of IC/ISBT. Direct applicator reconstruction was carried out on the CT images using multi-planar reconstruction (MPR). All treatment plans were based on a Flexitron afterloader unit. The activation step was set to 2 mm.
Table 1
The dose-volume constraints used for this study (Gy)
|
Total1
|
One fraction of IC/ISBT
|
HR CTV D90
|
≥ 80–87
|
≥ 6
|
Bladder D2cc
|
≤ 80–90
|
≤ 5.1
|
Rectum D2cc
|
≤ 65–75
|
≤ 4.3
|
Sigmoid D2cc
|
≤ 70–75
|
≤ 4.1
|
Bowel D2cc
|
-
|
≤ 4.3
|
1 The equivalent accumulated dose of EBRT and IC/ISBT at 2 Gy (EQD2). |
IPSA planning
IPSA provides a combination of source activation, dose normalization, dose optimization, and dose prescription. Thus, the optimization can be performed just after contouring and applicator reconstruction. Table 2 shows the initial optimization settings used in this study. HR CTV was identified as the Reference Target. Note that its minimum surface/volume doses (700 cGy) were set to be higher than the PD just for optimization, aiming to increase the coverage of the targets while remaining the dose to OARs unchanged as far as possible. When the plan was optimized, the dose to 90% of HR CTV (D90) would be normalized to 100% of the PD (600 cGy). The optimization parameters were adjusted and the calculation was repeated if the clinical objective was not achieved.
In Oncentra Brachy v4.3 and above, the IPSA optimization engine introduced a special parameter, dwell time deviation constraint (DTDC), which allows restriction of the difference in dwell times between adjacent dwell positions within each catheter. The DTDC value can be set from 0.0 to 1.0, where 0 is an unrestricted optimization and 1 is a homogeneous plan. Using DTDC can avoid the presence of isolated positions with extremely large dwell times. But studies have shown that a high value of DTDC may against target coverage and OARs sparing [18, 30]. In this study, the DTDC was set to 0.1.
Table 2
Dose volume objectives used for the IPSA plans
Contour
|
Min (cGy)
|
Weight
|
Max (cGy)
|
Weight
|
HR CTV (surface)
|
700
|
200
|
1500
|
10
|
HR CTV (volume)
|
700
|
200
|
2500
|
1
|
IR CTV (surface)
|
500
|
10
|
800
|
50
|
IR CTV (volume)
|
500
|
10
|
1500
|
20
|
Bladder (surface)
|
|
|
430
|
50
|
Rectum (surface)
|
|
|
400
|
30
|
Sigmoid (surface)
|
|
|
400
|
30
|
Bowel (surface)
|
|
|
400
|
30
|
HIPO planning
HIPO was only used for the optimization of the dose distribution in this study, hence the source dwell positions were set the same as those for IPSA. The optimization parameters were listed in Table 3. IR CTV and HR CTV were identified as the PTV and GTV, respectively. Similar to DTDC, the dwell time gradient restriction (DTGR) is a modulation restriction parameter for HIPO to restrict large fluctuations between dwell times in neighboring dwell positions. It is also a relative value between 0.0 and 1.0, reflecting the ‘weight’ of its importance in the optimization solution space [30]. The higher the value, the smaller the fluctuation [31]. However, to minimize adverse impact on target coverage and OARs sparing, the DTGR was set to 0.1 as well. Moreover, HIPO enables manual control of the sampling points settings for regions of interest (ROIs). For a high optimization precision, we increased the number of sampling points proportionally to the volumes of targets and OARs.
Table 3
Dose volume objectives used for the HIPO plans
Contour
|
Min (% PD)
|
Weight
|
Max (% PD)
|
Weight
|
Priority
|
HR CTV
|
140
|
100
|
500
|
0.1
|
5
|
IR CTV
|
100
|
10
|
200
|
50
|
6
|
Bladder
|
|
|
80
|
70
|
1
|
Rectum
|
|
|
70
|
50
|
2
|
Sigmoid
|
|
|
70
|
50
|
3
|
Bowel
|
|
|
70
|
50
|
4
|
Normal tissue
|
|
|
100
|
1
|
-
|
Plan evaluation
The dose volume parameters recommended by GEC ESTRO GYN were analyzed for all plans, including D90 (dose to 90% of HR CTV and IR CTV), V CTV,200 (the volume of HR CTV receiving 200% of the PD), D2cc (minimal dose received by the most irradiated 2 cc volume of bladder, rectum, sigmoid and bowel). The conformity index (COIN) was used to evaluate how well the PD covers the target volume and excludes nontarget volumes, which was calculated as follows: [32]
COIN = VCTV,ref2 / (VCTV × Vref),
where VCTV,ref is the volume of CTV that receives dose equal to or greater than PD; Vref is the volume receiving the PD. As the high dose region is a cause of concern, we defined a factor, localization of high dose volume (LHDV), to characterize how accurately the high dose regions are localized inside of HR CTV. The LHDV is the ratio of VCTV,200 to V200 (the total volume receiving 200% of the PD). In addition, the dwell time distribution and the proportion of tandem loading time in total loading time (Ttan/tot) were also analyzed.
For each patient, the plan assessment method described in Ref. [20] was adopted to quantitatively compare which of the two plans has a better performance. The method consists of two parts. The first is a graphical analysis providing a set of radar plots to show each quality score intuitively. The second is a total plan score weighting all quality scores to evaluate plan quality entirely. The quality score of each dosimetric parameter mentioned above can be calculated according to the following expression:

where Cj is the constraint value of objective j given in Table 4, and Pj is the corresponding plan value. For targets, a high Pj represents a high coverage, homogeneity or conformal index, resulting in a low Sj. Similarly, for OARs, a low Sj means a low dose to the OAR. Each quality score is represented by a point along the angle bisector of the corresponding objective in the radar plot. The distance between the point and the radar plot center corresponds to the score value. By connecting all the points, a polygon representing the plan quality is generated. The smaller is the polygon area, the higher is the plan quality.
The total plan score was defined as follows:

where wj is the weight of objective j, which reflects its importance in clinical treatment. As shown in Table 4, the weights used for this study were defined by a group of 2 professional treatment planners and 3 radiation oncologists based on clinical practice. The set of weights were proved to be consistent with our clinical preferences. The two-sided paired t-test was used to make statistical comparisons of different quality indices between the IPSA and HIPO plans.
Table 4
The scoring parameters used in the plan assessment method
Objective
|
Constraint
|
Weight
|
Bladder D2cc (Gy)
|
≤ 5.1
|
15%
|
Rectum D2cc (Gy)
|
≤ 4.3
|
20%
|
Sigmoid D2cc (Gy)
|
≤ 4.1
|
20%
|
Bowel D2cc (Gy)
|
≤ 4.3
|
15%
|
IR CTV D90 (Gy)
|
≥ 4
|
10%
|
HR CTV COIN
|
1
|
10%
|
LHDV
|
1
|
5%
|
Total loading time (s)
|
≤ 400*
|
5%
|
* The value was chosen only to obtain a quality score and show it in radar plot, with no actual meaning. |